Skip to main content
. 2022 Nov 25;15(12):1465. doi: 10.3390/ph15121465

Figure 2.

Figure 2

Androgen receptor (AR) antagonist with antitumor activity based on bicyclic imides containing the norbornene structure (compounds 2a–2f) [29,30,31] and bicyclic sultams (compounds 2g–h) [32].